Divi’s Laboratories announced that the US Food and Drug Administration (US-FDA) conducted a general cGMP inspection of the Company’s Unit-II manufacturing facility at Chippada Village, Bheemunipatnam Mandal, Visakhapatnam, Andhra Pradesh from 11 July 2024 to 19 July 2024.
The US-FDA inspection is successfully completed with one procedural observation, which will be addressed in the stipulated period of time.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Jul 19 2024 | 1:41 PM IST
